MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $128.33 (4.50% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016Roth CapitalReiterated RatingBuy$147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016HC WainwrightInitiated CoverageBuy$146.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015Deutsche BankDowngradeBuy -> Hold$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/31/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha